Treatment options expand for pulmonary arterial hypertension in scleroderma

LAS VEGAS – Scleroderma patients are at particularly high risk for developing pulmonary arterial hypertension, but treatment options are expanding, and with early referral to a PAH specialist, outcomes can be improved, according to Dr. Ronald...

Most data reassure regarding TNF inhibitors and cancer

LAS VEGAS – Concerns about use of a tumor necrosis factor inhibitor in a rheumatoid arthritis patient with a history of cancer are common, but the data are largely reassuring, according to Dr. Iain McInnes...

Lupus treatment: Get back to basics

LAS VEGAS – The future looks bright for lupus treatment given the extensive list of drugs and targets currently undergoing evaluation, but for now treatment remains largely an art, according to Dr. Richard Furie. "We...

Autoantibodies play role in myositis classification, treatment

LAS VEGAS – Autoantibodies and autoantibody subsets can be particularly helpful for classifying and treating patients with myositis, including those with myositis-associated interstitial lung disease, according to Dr. Chester V. Oddis. Many autoantibody subsets are...

Limited data support multiple myositis treatment options

LAS VEGAS – Corticosteroids remain the initial treatment of choice for myositis and myositis-associated interstitial lung disease, but immunosuppressive agents, intravenous immunoglobulin, and biologics can also play a role in the treatment of one or...

Pages